Open Accessibility Menu
Hide

COVID-19 Therapy

Monoclonal Antibodies and Paxlovid Oral Antiviral Tablet Available at BCH

If you are less than eight days from the onset of symptoms due to COVID-19 and are at high-risk for developing severe disease, you may be eligible for an outpatient therapy for COVID-19. Boulder Community Health (BCH) offers two COVID-19 Therapies: Monoclonal Antibody Infusion and Paxlovid Antiviral tablets. Please see the information below to determine your eligibility.

Monoclonal Antibody Infusion

Monoclonal antibody therapies are a one–time infusion that has been approved by the FDA via emergency use authorization. This therapy provides antibodies to aid in your immune response to COVID-19. While your body naturally makes antibodies to fight infection, it takes time for your body to make enough antibodies to fight a new infection like COVID-19. Monoclonal antibodies are made in a laboratory to fight a particular infection—in this case, COVID-19. They are given to patients to help fight the infection faster than your body could do on its own. Ideal people for this therapy have no or limited pre-existing antibodies to COVID-19.

You may be eligible for monoclonal antibody therapy if you are within 10 days (ideally 7 days) of COVID-19 symptom onset AND have a positive PCR test for COVID-19 AND are one of the following:

  • Vaccinated and Severely Immunocompromised and over 18 years old
  • Unvaccinated and over 18 years old with a clinical risk factor for COVID progression
  • Vaccinated and 65 years or older

Due to the limited supply of monoclonal antibodies, a medical provider's referral is required. If you are unsure if you might qualify, please call your primary care doctor or specialist. Click here for more information.

Return to Top

Paxlovid Antiviral Therapy

Paxlovid is another medicine for the treatment of mild-to-moderate COVID-19 approved by the FDA via emergency use authorization. Paxlovid is an anti-viral pill, which means it directly targets SARS-CoV-2, the virus that causes COVID-19. Directly targeting the virus with Paxlovid has been shown to significantly decrease the chances of hospitalization in individuals at high risk for progressing to severe disease due to COVID-19. This medication has several important drug-drug interactions that need to be reviewed by a provider.

You may be eligible for Paxlovid therapy if your symptoms of COVID-19 started within the last 5 days and you have a positive COVID-19 test (either home antigen test or laboratory PCR) and are one of the following:

  • Vaccinated and Severely Immunocompromised
  • Unvaccinated and over 18 years old with a clinical risk factor for COVID progression
  • Vaccinated and over 18 years old with a clinical risk factor for COVID progression
  • Vaccinated and 65 years or older

Click here for information on Paxlovid Therapy and immunocompromised patients and risk factors for COVID progression.

If you have COVID-19 and think you might be a candidate for Paxlovid antiviral pill based on the information above, please call your BCH Primary Care Doctor for a telehealth visit or if you don’t have a BCH Primary Care Doctor, call the BCH COVID-19 line at 303-415-8180where you will be screened to see if you are a candidate for therapy.

NOTE: The availability of these therapies in Colorado is determined at the federal level. According to the Colorado Department of Public Health and Environment (CDPHE), as of January 2022, the federal government is supplying an extremely limited quantity of these medications, significantly impacting the number of people who are able to receive therapeutic treatment. The CDPHE is hopeful that the supply of monoclonal antibody treatment and antivirals will ramp up significantly in the coming months.

Return to Top
Related Physicians